Sartorius Stedim Biotech and BD Diagnostics Strengthen Co-operation in the Area of Microbiological Diagnostics
Sartorius Stedim Biotech (SSB), a leading international pharma and biotech supplier, and BD Diagnostics, a segment of BD (Becton, Dickinson and Company), a leading global medical technology company, have announced a collaboration to develop, manufacture and market various ready-to-use, prefilled media products for microbiological applications in pharmaceutical, biotech and research laboratories.
“Through our agreement with BD, we have created an excellent collaboration. BD is known worldwide for its expertise in manufacturing and filling of microbial media. BD’s expertise combined with Sartorius Stedim Biotech’s know-how in polymeric technologies and applications will help us further extend our expert capabilities in the field of microbiological monitoring,” says Dominique Baly, member of the Sartorius Group Executive Committee.
Based on its many years of expertise in the development of membranes, SSB offers high-quality, single-use filter products for concentration of microbial contaminants in the lab. As part of this strategic collaboration, BD will fill special SSB single-use products with BD culture media and supply these to SSB as prepackaged products. In addition, the companies are exploring options of extending their existing business relationship by pursuing further innovative solutions in the field of microbiological diagnostics.
“The products we plan to develop under our agreement with SSB will enhance laboratory efficiencies for our pharmaceutical, biotech and research customers with these unique product offerings,” said Bob Ferguson, Vice President and General Manager, BD Diagnostics — Diagnostic Systems, Industrial Microbiology. “By combining SSB’s bioprocessing and filtration expertise with BD’s microbiological media capabilities, customers will benefit from improved lab productivity and standardization of sample processing.”
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...